Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 02 - 24 tags : Therapeutics save search
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
Published: 2022-02-24 (Crawled : 01:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -4.06%
H: 0.0%
C: 0.0%
SGMO | $0.5143 6.02% 5.68% 1M
|
Health Technology
|
| O: -2.04%
H: 0.0%
C: 0.0%
financial results therapeutics report results
Cyteir Therapeutics Announces the Appointment of Stephen Sands to Board of Directors
Published: 2022-02-24 (Crawled : 01:00) - biospace.com/
CYT | $3.02 2.65% 1M
|
Manufacturing
|
| O: -3.44%
H: 0.0%
C: 0.0%
ces therapeutics
Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
Published: 2022-02-24 (Crawled : 00:00) - biospace.com/
JSPR | $21.61 -6.89% -7.4% 65K
|
|
| O: 1.44%
H: 0.0%
C: 0.0%
jsp191 phase 1b therapeutics presentation cel phase 1 therapy aml phase 2b
Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis
Published: 2022-02-24 (Crawled : 23:00) - globenewswire.com
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: 0.71%
H: 13.92%
C: 13.8%
pln-7480 phase 2 fibrosis trial therapeutics positive enroll phase 2b
Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome
Published: 2022-02-24 (Crawled : 20:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -4.06%
H: 0.0%
C: 0.0%
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: -3.66%
H: 8.0%
C: 6.5%
phase 2 trial therapeutics syndros enroll
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-02-24 (Crawled : 19:00) - biospace.com/
EWTX | $15.23 -1.42% -1.44% 540K
|
Manufacturing
|
| O: -3.04%
H: 8.25%
C: 7.89%
financial results therapeutics report results
NeuroSense Therapeutics to Present at American Society for Experimental Neurotherapeutics Annual Meeting on March 3rd
Published: 2022-02-24 (Crawled : 14:30) - prnewswire.com
NRSN | $1.435 -5.59% -5.92% 120K
|
|
| O: -10.46%
H: 5.84%
C: 2.19%
america therapeutics
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business UpdateConference call to be held Tuesday, March 1, 2022 at 8:30 AM ET
Published: 2022-02-24 (Crawled : 14:00) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -3.82%
H: 0.0%
C: 0.0%
day financial results conference therapeutics results
Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress
Published: 2022-02-24 (Crawled : 13:30) - globenewswire.com
OTLK P | $8.15 -1.69% -1.72% 270K
|
Health Technology
|
| O: 1.42%
H: 15.73%
C: 14.69%
therapeutics
Vaccinex, Inc. to Present at CHDI’s 17th Annual HD Therapeutics Conference Meeting
Published: 2022-02-24 (Crawled : 13:00) - globenewswire.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: -6.15%
H: 9.02%
C: 9.02%
conference therapeutics vaccine
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Published: 2022-02-24 (Crawled : 13:00) - globenewswire.com
PLRX | $12.51 2.63% 2.56% 310K
|
Health Technology
|
| O: -6.46%
H: 7.64%
C: 2.06%
conference therapeutics
Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis
Published: 2022-02-24 (Crawled : 13:00) - biospace.com/
TRVI | $2.82 5.03% 4.79% 140K
|
Health Technology
|
| O: 8.7%
H: 28.6%
C: -2.0%
treatment fibrosis trial therapeutics report chronic cough
ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022
Published: 2022-02-24 (Crawled : 13:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -2.57%
H: 8.83%
C: 8.24%
financial results conference therapeutics results
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce the Submission of a Marketing Authorization Application to the European Medicines Agency for PRX-102 for the Treatment of Fabry Disease
Published: 2022-02-24 (Crawled : 12:30) - prnewswire.com
PLX | $1.15 1.77% -2.61% 450K
|
Health Services
|
| O: -5.77%
H: 3.69%
C: 1.25%
prx-102 treatment europe application rare therapeutics disease authorization iot submission prx012
Karuna Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides General Business Update
Published: 2022-02-24 (Crawled : 12:30) - biospace.com/
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: -2.07%
H: 3.23%
C: -3.69%
financial results therapeutics report results
ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus’ Gene Therapy Business Due to Market Conditions
Published: 2022-02-24 (Crawled : 12:00) - globenewswire.com
ARYD | $11.31 -0.09% 25K
|
|
| O: -0.81%
H: 0.0%
C: -0.61%
FOLD F | $10.62 2.81% 2.73% 2.5M
|
Health Technology
|
| O: -5.94%
H: 9.41%
C: 9.28%
acquisition gene therapy therapeutics therapy acquisition corp
SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights
Published: 2022-02-24 (Crawled : 12:00) - globenewswire.com
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: -3.92%
H: 14.21%
C: 13.94%
financial results therapeutics work report results
Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update
Published: 2022-02-24 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -4.06%
H: 0.0%
C: 0.0%
KYMR | $33.965 -3.29% -3.4% 630K
|
Health Technology
|
| O: -2.56%
H: 13.17%
C: 12.27%
financial results ces therapeutics results
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
Published: 2022-02-24 (Crawled : 12:00) - globenewswire.com
FOLD F | $10.62 2.81% 2.73% 2.5M
|
Health Technology
|
| O: -5.94%
H: 9.41%
C: 9.28%
financial results ces therapeutics results
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
Published: 2022-02-24 (Crawled : 12:00) - globenewswire.com
ACRS | $1.25 1.63% 1.6% 580K
|
Health Technology
|
| O: -5.07%
H: 13.03%
C: 10.83%
financial results therapeutics report results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.